Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 08, 2022

BUY
$2.73 - $4.92 $365 - $659
134 Added 0.87%
15,468 $36,000
Q2 2022

Aug 04, 2022

SELL
$2.8 - $7.67 $106 - $291
-38 Reduced 0.25%
15,334 $46,000
Q1 2022

May 05, 2022

SELL
$6.01 - $8.54 $158,267 - $224,892
-26,334 Reduced 63.14%
15,372 $104,000
Q4 2021

Feb 02, 2022

SELL
$7.11 - $9.64 $2,936 - $3,981
-413 Reduced 0.98%
41,706 $348,000
Q3 2021

Nov 02, 2021

BUY
$5.04 - $8.73 $997 - $1,728
198 Added 0.47%
42,119 $313,000
Q2 2021

Aug 02, 2021

SELL
$6.58 - $10.66 $46,145 - $74,758
-7,013 Reduced 14.33%
41,921 $285,000
Q4 2020

Feb 08, 2021

SELL
$6.37 - $10.33 $4,459 - $7,231
-700 Reduced 1.41%
48,934 $343,000
Q2 2020

Aug 07, 2020

BUY
$4.17 - $7.58 $63,709 - $115,807
15,278 Added 44.47%
49,634 $342,000
Q1 2020

May 06, 2020

BUY
$2.91 - $8.7 $35,566 - $106,331
12,222 Added 55.22%
34,356 $163,000
Q4 2019

Feb 05, 2020

SELL
$2.81 - $9.21 $1,686 - $5,526
-600 Reduced 2.64%
22,134 $193,000
Q3 2019

Nov 07, 2019

BUY
$3.33 - $4.93 $3,829 - $5,669
1,150 Added 5.33%
22,734 $76,000
Q2 2019

Aug 09, 2019

SELL
$4.3 - $6.73 $2,150 - $3,365
-500 Reduced 2.26%
21,584 $107,000
Q1 2019

May 08, 2019

SELL
$3.43 - $6.87 $1,372 - $2,748
-400 Reduced 1.78%
22,084 $137,000
Q4 2018

Feb 08, 2019

SELL
$2.69 - $6.71 $807 - $2,013
-300 Reduced 1.32%
22,484 $76,000
Q2 2018

Aug 10, 2018

SELL
$7.27 - $21.88 $1,090 - $3,282
-150 Reduced 0.65%
22,784 $175,000
Q4 2017

Feb 13, 2018

BUY
$12.52 - $17.82 $218,273 - $310,673
17,434 Added 316.98%
22,934 $292,000
Q2 2017

Aug 11, 2017

BUY
N/A
5,500
5,500 $77,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.